MOTS-C (40 mg Vial)

MOTS-C Information Chart

MOTS-C is studied at 200 mcg–1 mg in educational research settings. A 40 mg vial prepared with bacteriostatic water yields about 13.33 mg/mL. Most research approaches explore gradual increases over roughly 10 weeks. This information is for research and educational use only.

MOTS-C is a 16–amino-acid mitochondrial-derived peptide (MDP) that acts as a metabolic regulator, primarily through AMPK activation. Preclinical studies show it enhances insulin sensitivity, promotes fat oxidation, improves exercise capacity, and supports age-related metabolic research. No clinical trials have been completed in humans to date. This educational material presents a once-daily subcutaneous approach with gradual progression.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read MOTS-C Peptide: Benefits, Uses, Side Effects, Research, and Mechanisms.

Educational guide for research preparation and daily administration

Standard / Gradual Approach (3 mL = ~13.33 mg/mL)

Week	Daily Amount (mcg)	Units (per administration) (mL)
Weeks 1–2	200 mcg (0.2 mg)	1.5 units (0.015 mL)
Weeks 3–4	400 mcg (0.4 mg)	3 units (0.03 mL)
Weeks 5–6	600 mcg (0.6 mg)	4.5 units (0.045 mL)
Weeks 7–8	800 mcg (0.8 mg)	6 units (0.06 mL)
Weeks 9–10+	1,000 mcg (1.0 mg)	7.5 units (0.075 mL)

Frequency: Apply once daily subcutaneously. Stay at each level for approximately 2 weeks before increasing, and monitor for any adverse reactions. Frequency: Apply once daily subcutaneously. Stay at each level for approximately 2 weeks before increasing, and monitor for any adverse reactions.

For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Preparation Steps

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Plan based on an 8–16 week daily research schedule with gradual progression.

Concise summary of the once-daily regimen.

Goal: Support metabolic homeostasis, insulin sensitivity, and age-related physical performance based on preclinical evidence.
Schedule: Daily subcutaneous applications for 8–12 weeks (extend to 16 weeks if desired).
Amount Range: 200–1,000 mcg daily with gradual progression over 10 weeks.
Preparation: 3.0 mL per 40 mg vial (~13.33 mg/mL) for accurate measurements.
Storage: Lyophilized frozen at −20 °C (−4 °F); prepared solution refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw.

Suggested daily progression approach based on animal-to-human research observations.

Start: 200 mcg daily for 2 weeks.
Progression: Increase by ~200 mcg every 2 weeks: 400 mcg (Weeks 3–4), 600 mcg (Weeks 5–6), 800 mcg (Weeks 7–8).
Target: Up to 1,000 mcg (1.0 mg) daily by Weeks 9–10+ if well tolerated.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Timing: Any consistent time; rotate application areas.

Proper storage preserves peptide quality and potency.

Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; include desiccant if available to minimize moisture exposure.
Prepared Solution: Refrigerate at 2–8 °C (35.6–46.4 °F); peptide stability may decrease at room temperature. Use within 7 days for best potency.
Aliquoting: Prepare single-use portions and freeze at −20 °C (−4 °F) if needed; avoid repeated temperature changes.

Allow vials to reach room temperature before opening to reduce condensation uptake.

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each application; dispose of used devices in a sharps container.
Rotate application areas (abdomen, thighs, upper arms) to reduce local irritation and prevent tissue changes.
Apply slowly; wait a few seconds before withdrawing the needle.
Document daily amount, application area, and any observations to maintain consistency.
Discontinue use and consult a medical professional if any concerning symptoms arise.

MOTS-C functions as a metabolic “stress signal” that helps optimize energy usage during nutrient stress or exercise. Its primary mechanism is AMPK activation through inhibition of the folate cycle, causing accumulation of AICAR (an AMP analog). Activated AMPK shifts cells into an energy-efficient mode — enhancing glucose uptake, fatty-acid oxidation, and mitochondrial respiration while downregulating fat storage and gluconeogenesis. MOTS-C can also translocate to the cell nucleus under stress conditions and regulate antioxidant and stress-response genes. This retrograde signaling from mitochondria to nucleus increases expression of cytoprotective enzymes, helping cells cope with oxidative stress. Research indicates MOTS-C may also influence mTOR and inflammatory pathways, contributing to lifespan and healthspan effects. Its actions resemble those of exercise and metformin at a cellular level, making it of interest for metabolic disorders, obesity, and aging research.

Observations from preclinical literature (no human clinical trials completed to date).

Bone & Immunity: Supports osteoblast activity, influences osteoclast formation, affects immune aging pathways, and supports pancreatic islet cell research in autoimmune diabetes models.
Organ Protection: Supports liver fat regulation, cardiac function, and may influence cognitive function in preliminary studies.
Physical Performance: Supports exercise capacity and age-related physical function in research models.
Post-Menopausal Metabolism: Supports metabolic regulation in ovariectomized mice; influences menopause-related fat gain and insulin resistance pathways.
Weight & Fat Reduction: Supports research on weight regulation and reduces visceral fat in obese mice through increased energy expenditure and fat oxidation.
Metabolic Health: Improves insulin sensitivity and glucose metabolism in mouse models; supports metabolic balance and reduces diet-induced insulin resistance.

Complementary strategies for best outcomes based on MOTS-C’s metabolic mechanisms.

Pair with a balanced, protein-forward diet tailored to energy needs.
Combine resistance training and aerobic activity to reinforce metabolic adaptations and AMPK signaling.
Prioritize sleep (7–9 hours) and stress management to support mitochondrial health and recovery.
Consider intermittent fasting or caloric restriction, which may influence MOTS-C-related metabolic effects.

General subcutaneous guidance from clinical best-practice resources.

Site Preparation: Clean the vial stopper and skin area with alcohol; allow to dry completely.
Application Position: Pinch a skinfold; place the needle at 90° (45° if very lean) into subcutaneous tissue.
Administration: Do not aspirate for subcutaneous applications; apply slowly and steadily over a few seconds.
After Application: Withdraw the needle at the same angle; apply gentle pressure if bleeding occurs (do not rub).
Site Rotation: Rotate areas systematically (abdomen at least 2 inches from navel, outer thighs, back of upper arms) to avoid irritation and tissue changes.
Disposal: Dispose of used devices immediately in a proper sharps container (never reuse needles).

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. MOTS-C is an experimental compound; no clinical trials have been completed in humans. Always consult qualified healthcare providers before starting any new therapy.

Cell Metabolism (2015)

— The mitochondrial-derived peptide MOTS-C promotes metabolic homeostasis and reduces obesity and insulin resistance (Lee C, Zeng J, Drew BG, et al.)

Journal of Translational Medicine (2023)

— Mitochondria-derived peptide MOTS-C: effects and mechanisms related to stress, metabolism and aging (Wan W, Zhang L, Lin Y, et al.)

Journal of Molecular Medicine (2019)

— MOTS-C peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction (Lu H, Wei M, Zhai Y, et al.)

Nature Communications (2021)

— MOTS-C is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Reynolds JC, Lai RW, Woodhead JST, et al.)

Frontiers in Physiology (2023)

— Role of MOTS-C in the regulation of bone metabolism (Yi X, Hu G, Yang Y, et al.)

Cognitive Vitality Reports (2021)

— MOTS-C (Cognitive Vitality Profile) – Alzheimer’s Drug Discovery Foundation (ADDF)

USADA Spirit of Sport (2023)

— What is the MOTS-C peptide? – U.S. Anti-Doping Agency education article

CDC Vaccine Administration Guidelines

— Subcutaneous route guidance (angle, site selection, no aspiration)